Biotech & Medtech
Biotech & Medtech news — Thursday 19 November 2026
25 stories from 5 sources, every one in English. Each links to its publisher.
-
Who Should Make Medical-Necessity Decisions: AI, Insurers or Treating Physicians?
On a panel at HLTH, experts discussed prior authorization denials and who should make the final call. The post Who Should Make Medical-Necessity Decisions: AI, Insurers or Treating Physicians? appeared first on MedCity News .
-
Opinion: The U.S. lost measles elimination status. The next Congress should help restore it
On Tuesday, the Pan American Health Organization (PAHO) announced that the United States had lost its measles elimination status, a distinction it had held for 26 years. The same lineage of the virus has spread from person to person in the…
-
Independent Benefits Platform Leader: Market Forces Prevent Employers From Getting Best Solution
On a panel on employee benefits Ali Diab, CEO of Collective Health, spoke plainly about the market forces that hamper self-insured employers from designing the best employee benefits. The post Independent Benefits Platform Leader: Market…
-
Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria
When it comes to preventing malaria, researchers and public health officials have been hopeful about the potential of a monoclonal antibody, one injection of which could provide recipients with several months of protection against the…
-
FDA Approval for Sanofi Drug Marks an Important First in Rare Disease
Sanofi’s Infilbray is now approved for treating Gaucher disease type 3. The brain-penetrating small molecule is the first FDA-approved therapy for the neurological symptoms of this rare enzyme deficiency. The post FDA Approval for Sanofi…
-
Sanofi gains FDA clearance for Gaucher disease pill
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
-
STAT+: Lawmakers want U.S. biotech to outcompete China
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. With Heidi Overton out, who’s gonna lead the FDA? We should endeavor a guess, March Madness-style. STAT Madness…
-
STAT+: Peptide market poised to explode with new Hims and Noom launches
Peptides are poised to go mainstream with this week’s launches from telehealth companies Hims & Hers and Noom, both of which announced they will be offering prescriptions for eligible patients. Synthetic peptides are a broad category of…
-
China could ‘corner’ biopharmaceutical sector with new plan, US panel warns
A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”
-
STAT+: MAHA PAC’s steakhouse spend
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. House Republicans cancelled Friday’s…
-
National Academies report calls for faster decisions on publication retractions and corrections
A new report commissioned by the National Academies of Sciences, Engineering, and Medicine urged the scientific community to respond more aggressively to claims of errors or manipulated data in published research, saying that papers…
-
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
-
When GLP-1 Costs Mask the Value of Care Management
What would your fund’s claims report look like this year without GLP-1s? It’s worth asking before deciding whether your care management program is working. The post When GLP-1 Costs Mask the Value of Care Management appeared first on…
-
STAT+: Epic defends competitive practices; promises AI access to records
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Today…
-
STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they have finished…
-
Sanders’ ‘Medicare for All’ plan accrues more liberate and moderate support in Congress
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Tons of news coming from the nation’s capitol as Democrats set their agenda for next year, but it’s worth highlighting what…
-
STAT+: Merck, Isomorphic Labs partner to develop oncology drug candidates
Merck and Isomorphic Labs , the artificial intelligence drug designer built on a Nobel winning technology that can model how molecules will bind to proteins, said Thursday that they are entering into a research collaboration to discover…
-
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content. Erasca’s pitch is straightforward: The…
-
Opinion: STAT+: I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins
At the American Heart Association’s recent annual meeting, the overarching theme coming from the center stage, bathed in Pantone red, was one of high-profile neutral findings . As I listened to the results of the STREAM trial — which found…
-
STAT+: Before midterm losses, MAHA spent on itself instead of candidates
WASHINGTON — When Tony Lyons, leader of the largest Make America Healthy Again organizations in Washington, spoke to supporters the day after the election, he was sullen. “MAHA was up against some of the most powerful and best funded…
-
A Dual-SOM Learner Model of Instructional Efficiency within Cognitive Load Theory
arXiv:2611.23795v1 Announce Type: cross Abstract: This paper presents a novel methodological framework, integrating a dual self-organising map (SOM) neural network architecture with Cognitive Load Theory (CLT), for assessing instructional…
-
Analysis of the (1+1)-EA-ES-Bilevel on Mixed Discrete-Continuous Optimization Problems with Interactions
arXiv:2611.24251v1 Announce Type: new Abstract: Mixed discrete-continuous optimization problems can pose challenges -- especially for previous integrated approaches -- when interactions cause beneficial discrete changes to be rejected…
-
Old Matches, New Frames: Schedule-Gated Stereo Memory from Human Vision to Machine Matching
arXiv:2611.24848v1 Announce Type: new Abstract: Human vision and video stereo networks both reuse disparity evidence across time, yet a refresh of the input can invalidate a match formed milliseconds earlier. What tells a system whether an…
-
Incremental Speciation in Evolutionary Red Teaming of Large Language Models
arXiv:2611.23949v1 Announce Type: new Abstract: Speciation maintains distinct subpopulations in evolutionary search through similarity-based grouping and species-aware parent selection. For text-based individuals, niches depend on both the…
-
Programmable functional RNA design with a virtual scientist
Nature Biotechnology, Published online: 19 November 2026; doi:10.1038/s41587-026-03362-3 RhoAgent designs functional RNA molecules by constraining secondary structure, base interactions and functional motifs.